ArticleInternational journal of hematology2025

DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myeloma.

Kazutaka Sunami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.